A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer

BACKGROUND: Pancreatic cancer is the fourth most common cause of cancer related death in Western countries. Advantages in surgical techniques, radiation and chemotherapy had almost no impact on the long term survival of affected patients. Therefore, the need for better treatment strategies is urgent...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Mihaljevic, Andre, Büchler, Peter, Harder, Jan, Hofheinz, Ralf, Gregor, Michael, Kanzler, Stephan, Schmiegel, Wolff, Heinemann, Volker, Endlicher, Esther, Klöppel, Günter, Seufferlein, Thomas, Geissler, Michael
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2009
Teme:
Study Protocol
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2661037/
https://ncbi.nlm.nih.gov/pubmed/19133157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2482-9-1
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items